Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch & Lomb Technolas

This article was originally published in The Gray Sheet

Executive Summary

Expanded indication for 217A excimer laser system - to treat hyperopia with or without astigmatism - is undergoing final labeling review by FDA, B&L notes Oct. 18. Firm also announces U.S. debut of its SofLens multi-focal contact lens. Cleared via 510(k) in May, the presbyopic lens will allow improved fit compared with B&L's Occasions multi-focal lenses, which provide near and far vision in different zones. Corporate revenues for the third quarter (ended Sept. 28) are $466.7 mil., up 11%, including a 13% advance in contact lens sales, B&L reports Oct. 17. Earnings of $9.4 mil. are off 59.6%, including $16.7 mil. in after-tax restructuring charges and write-offs...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT017320

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel